Behavioural Intervention
Lifestyle Interventions for Mild Cognitive Impairment
Recruiting0 awards
Waterloo, Ontario
This trial will test an online 6-month exercise and nutrition program to improve memory and thinking abilities in older adults with declining mental function. 140 people aged 65-80 will be recruited and receive different combinations of lifestyle interventions. Assessments will be conducted online and from home.
Monoclonal Antibodies
MEDI6570 for Heart Attack
Recruiting0 awardsPhase 2
Richmond, IN
This trial is testing MEDI6570, a new medication that aims to reduce inflammation in people who have had a heart attack. The goal is to see if it can help prevent more heart problems. The study will help decide how to use this medication in future treatments.
Placebo +1 More for Prostate Cancer
Recruiting0 awardsPhase 2
Jeffersonville, Indiana
Randomized, double-blind, placebo controlled, dose finding Phase 2 study comparing oral daily dosing of VERU-944 after a week of loading (daily dosing) with placebo to ameliorate the vasomotor symptoms resulting from androgen deprivation therapy in men with advanced prostate cancer
Proteasome Inhibitor
Carfilzomib +1 More for Multiple Myeloma
Recruiting3 awardsPhase 1 & 2
Cincinnati, Ohio
Relapsed/refractory Multiple Myeloma (MM) is an incurable disorder with a poor prognosis. Carfilzomib is a novel proteasome inhibitor with activity in this setting. Panobinostat is a pan-deacetylase inhibitor which has shown synergistic cytotoxicity in vitro and in vivo with proteasome inhibitors. The combination should enhance the activity of both agents against myeloma cells. In Phase I, the optimal doses of the combination of carfilzomib and panobinostat will be determined. Assuming this combination is feasible, the Phase II portion will proceed using the doses determined in Phase I.
Popular Filters
Phase 3 Trials
Local Anesthetic
HTX-011 for Postoperative Pain
Recruiting3 awardsPhase 3
Dayton, Ohio
This is a Phase 3, randomized, double-blind, saline placebo- and active-controlled, multicenter study to evaluate the analgesic efficacy and safety of HTX 011 administered via local administration into the surgical site in subjects undergoing unilateral open inguinal herniorrhaphy.
Monoclonal Antibodies
AZD0901 for Stomach Cancer
Recruiting2 awardsPhase 3
London, Ontario
This trial aims to compare the effectiveness and safety of AZD0901 with other treatment options for patients with advanced stomach or gastroesophageal junction cancer that has spread, and that expresses a specific protein
CFTR Modulator
VX-121 + Tezacaftor + Deutivacaftor for Cystic Fibrosis
Recruiting2 awardsPhase 3
Cincinnati, Ohio
This trial tests a combination of three drugs for cystic fibrosis patients with a specific genetic mutation. The drugs work together to fix the faulty protein in their cells, helping their lungs and other organs function better. Trikafta is a combination of three drugs (elexacaftor, tezacaftor, and ivacaftor) that target the F508del mutation in the CFTR gene.
Monoclonal Antibodies
Tanezumab +1 More for Osteoarthritis
Recruiting2 awardsPhase 3
Huntsville, Alabama
The purpose of this study is to compare the long-term joint safety and efficacy (pain relief) of the investigational study drug, tanezumab compared to non-steroidal anti inflammatory drugs (NSAIDs) in subjects with osteoarthritis of the hips or knees.
Trials With No Placebo
Device
Intrinsic Antitachycardia Pacing (iATP) Therapy for Ventricular Tachycardia
Recruiting1 award3 criteria
Cincinnati, Ohio
Medtronic is sponsoring the Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS) to further confirm safety and effectiveness of ventricular iATP therapy in routine clinical practice, following commercial release of iATP-capable devices. The iATP PAS is conducted within Medtronic's Product Surveillance Registry platform (NCT01524276).
Monoclonal Antibodies
AZD0901 for Stomach Cancer
Recruiting2 awardsPhase 3
London, Ontario
This trial aims to compare the effectiveness and safety of AZD0901 with other treatment options for patients with advanced stomach or gastroesophageal junction cancer that has spread, and that expresses a specific protein
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.